Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Article ID	Journal	Published Year	Pages	File Type
8656974	Atherosclerosis	2018	7 Pages	PDF

Abstract

Our data suggest an independent association of elevated UA with long-term MACE in ACS patients undergoing PCI. Whether lowering UA might be beneficial remains to be elucidated in large clinical trials.

Keywords

EGFR non-ST-elevation acute coronary syndrome NSTE-ACS IDI MACE NRI STEMI PCI TIA HDL-C ARB ACS ACE-I LDL-C ASs angiotensin-converting-enzyme inhibitor acetylsalicylic acid Uric acid ST-elevation myocardial infarction Net reclassification improvement Integrated discrimination improvement coronary artery disease transient ischemic attack major adverse cardiovascular event Acute coronary syndrome CAD high-density lipoprotein cholesterol percutaneous coronary intervention angiotensin-receptor blocker estimated glomerular filtration rate Hyperuricemia Creatine kinase Low-density lipoprotein cholesterol

Related Topics

Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine

Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Authors

Maximilian Tscharre, Robert Herman, Miklos Rohla, Christina Hauser, Serdar Farhan, Matthias K. Freynhofer, Kurt Huber, Thomas W. Weiss,